The American Academy of Pediatrics (AAP) recommends respiratory syncytial virus (RSV) immunization for:
- infants <8 months of age born during or entering their first RSV season if:
- pregnant parent did not receive RSVpreF vaccine during this pregnancy,
- pregnant parent’s RSVpreF vaccination status is unknown, or
- infant was born <14 days after the pregnant parent’s RSVpreF vaccination
- infants and children 8 through 19 months of age at high risk of severe RSV disease and entering their second RSV season, regardless of the RSV vaccination status of the pregnant parent or the child’s prior receipt of nirsevimab or clesrovimab when <8 months of age in their first RSV season. High-risk criteria include the following:
- Children with chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) at any time during the 6-month period before the start of the second RSV season
- Children with severe immunocompromise
- Children with cystic fibrosis who have either:
- manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable), or
- weight-for-length that is less than the 10th percentile
- American Indian or Alaska Native children